FoI Number
2023-337
Subject
Rheumatology Drugs
Date Received
07/09/2023
Request and Response
  1. Wilmington Healthcare is analysing the usage of biologic and biosimilar products within Rheumatology. It would be really helpful if you could provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:
Abatacept [Orencia] 1
Adalimumab [Humira] 1
Adalimumab Biosimilars 29
Apremilast [Otezla] 0
Baricitinib [Olumiant] 0
Bimekizumab [Bimzelx] 0
Certolizumab [Cimzia] 5
Etanercept [Enbrel] 1
Etanercept Biosimilars 15
Filgotinib [Jyseleca] 1
Golimumab [Simponi] 1
Guselkumab [Tremfya] 0
Infliximab [Remicade] 0
Infliximab Biosimilars 3
Ixekizumab [Taltz] 0
Risankizumab [Skyrizi] 0
Rituximab [MabThera] 1
Rituximab Biosimilars 0
Sarilumab [Kevzara] 0
Secukinumab [Cosentyx] 4
Tocilizumab [Ro Actemra] 2
Tofacitinib [Xeljanz] 1
Upadacitinib [Rinvoq] 0
Ustekinumab [Stelara] 1